medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2006, Number 07

<< Back Next >>

Ginecol Obstet Mex 2006; 74 (07)

Comparative study of overactive bladder prevalence in patients younger than 50 years with and without hyperprolactinemia

Solano SSR, Velázquez SMP, Rodríguez CS, Kunhardt RJ

Language: Spanish
References: 16
Page: 345-348
PDF size: 256.35 Kb.


ABSTRACT

Objective: To determine if the hyperprolactinemia is associated with idiopathic overactive bladder. Patients and methods: We performed a transversal and analytic two groups study. We included all the patients whom plasma levels of prolactin were measured in the National Institute of Perinatology from March 1st to May 31, 2005 and fulfilled the selection criteria. To all these patients we applied a questionnaire of eight questions for the overactive bladder diagnostic. We used chi square statistical technique to establish if hyperprolactinemia is associated with the overactive bladder. Results: One hundred sixty years patients were studied, establishing a relative prevalence of 2.82 (IC 95%: 1.45-3.17), determining association between the variables. Conclusions: hyperprolactinemia is associated with overactive bladder.


REFERENCES

  1. Abrams P, Cardodo I, Fall M, et al. The standardization of terminology of lower urinary tract function: Report from the standardization sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-78.

  2. Farrar DJ, Whileside CG, Osborne JL, Turner-Warwick RT. Urodynamic analysis of micturition symptoms in the female. Surg Gynecol Obstet 1975;141:875-7.

  3. Espuña M, Salinas J. Tratado de uroginecología. 1a ed. Montserrat: Ars Medica, 2004;pp:159-60.

  4. Whorwell PJ, Lupton EW, Erauran D, Wilson K. Bladder smooth muscle dysfunction in patients with irritable bowel syndrome. Gut 1986;27:1014-7.

  5. Walters M, Karram M. Urogynecology and reconstructive pelvic surgery. 2nd edition. Chicago: Mosby, 1999;pp24,298.

  6. Abrams P. Detrusor instability and bladder outlet obstruction. Neurourol Urodyn 1985;4:317.

  7. Pillai NP, Ramaswamy S, Gopalakrishnan V, Ghosh MN. Contractile effect of prolactin on Guinea pig isolated ileum. Eur J Pharmacol. 1981;72:11-16.

  8. Skrabanek P, Powell D. Substance P in obstetrics and gynecology. Obstet Gynecol. 1983;61:641-6.

  9. Walters CA, Daly DC, Chapitis J, et al. Human myometrium: a new potential source of prolactin. Am J Obstet Gynecol 1983;147:639-44.

  10. Sauro MD, Zorn NE. Prolactin induces proliferation of vascular smooth muscle cells through a protein kinase C-dependent mechanism. J Cell Physiol 1991;148:133-8.

  11. Sauro MD, Bing B, Zorn NE. Prolactin induces growth-related gene expression in rat aortic smooth muscle in vivo. Eur J Pharmacol 1992;225:351-4.

  12. Nowak RA, Rein MS, Heffner LJ, Friedman AJ, Tashjian AH Jr. Production of prolactin by smooth muscle cells cultured from human uterine fibroid tumors. J Clin Endocrinol Metab 1993;76:1308-13.

  13. Nohara A, Ohmichi M, Koike K, et al. Prolactin stimulates mitogen-activated protein kinase in human leiomyoma. Biochem Biophys Res Commun 1997;238:473-7.

  14. Nowak RA, Mora S, Diehl T, Rhoades AR, Stewart EA. Prolactin is an autocrine or paracrine growth factor for human myometrial and leiomyoma cells. Gynecol Obstet Invest 1999;48:127-32.

  15. Meli R, Gualillo O, Raso GM, Di Carlo R. Further evidence for the involvement of prolactin in the inflammatory response. Life Sci 1993;53:105-10.

  16. Coyne KS, Margolis MK, Zyczynski T, Elinoff V, Roberts R. Validation of an OAB screener in a primary care patient population in the US. Poster to be presented at: Annual Meeting of the International Continence Society. Paris, 2004.




2020     |     www.medigraphic.com